CHMP recommends EU approval of Roche ’s Polivy combination for people with previously untreated diffuse large B-cell lymphoma
Polivy plus R-CHP showed first clinically meaningful improvement in PFS with comparable safety in people with previously untreated diffuse large B-cell lymphoma (DLBCL) over the standard of care in more than 20 yearsApproximately 40% of people with previously untreated DLBCL are not cured with the current standard of care and face a poor prognosis [1,2]Recommendation is based on pivotal data from the phase III POLARIX studyBasel, 25 March 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency ’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Pol...
Source: Roche Media News - March 25, 2022 Category: Pharmaceuticals Source Type: news
Janssen Seeks Approval of a New Indication for IMBRUVICA ® (ibrutinib) for Use in Patients with Untreated Mantle Cell Lymphoma
BEERSE, BELGIUM, 8 March 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of a Type II variation application to the European Medicines Agency (EMA) seeking approval of a new indication for IMBRUVICA® (ibrutinib) in combination with bendamustine and rituximab (BR) for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are unsuitable for autologous stem cell transplantation (ASCT).Ibrutinib is a once-daily Bruton's tyrosine kinase (BTK) inhibitor that is currently approved for patients with MCL who have received at least one prior lin...
Source: Johnson and Johnson - March 8, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Study Supports Opdivo as Second-Line Mesothelioma Treatment
When the effectiveness of first-line chemotherapy fails and malignant mesothelioma returns, more patients could soon turn with confidence to a proven, second-line treatment.
The first phase III, placebo-controlled, double-blind clinical trial studying the safety and efficacy of Opdivo, the immunotherapy drug known generically as nivolumab, has raised the level of confidence in this option for patients with relapsed disease.
“The evidence is robust, the survival significant,” Dr. Dean Fennell, chair of Thoracic Medical Oncology, University of Leicester and University Hospitals in the United Kingdom, told The Mesot...
Source: Asbestos and Mesothelioma News - November 2, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news
What Is Non-Hodgkin's Lymphoma?
Title: What Is Non-Hodgkin ' s Lymphoma?Category: Diseases and ConditionsCreated: 12/31/1997 12:00:00 AMLast Editorial Review: 10/6/2021 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - October 6, 2021 Category: Cancer & Oncology Source Type: news
What 9/11 Survivors and First Responders Have Taught Us About Public Health in the 20 Years Since the Attacks
Dr. David Prezant was knocked fully airborne at 9:59 on the morning of Sept. 11, 2001. He didn’t see the impact coming, but he felt it when it hit—and it nearly killed him.
Little more than an hour earlier, Prezant, then the deputy chief medical officer of the Fire Department of New York, was headed for his usual workplace at the FDNY’s Office of Medical Affairs, just across the Manhattan Bridge in Brooklyn. He had already heard that a plane had hit the North Tower of the World Trade Center, and he reckoned that it was an accident. By the time he reached his office, however, the South Tower had been struc...
Source: TIME: Health - September 10, 2021 Category: Consumer Health News Authors: Jeffrey Kluger and Tara Law Tags: Uncategorized healthscienceclimate Source Type: news
Social Security Adds Pericardial Mesothelioma to Disabilities List
The U.S. Social Security Administration has added pericardial mesothelioma to its Compassionate Allowances list, accelerating the disabilities application process for this very rare cancer.
Its decision was prompted by the work of Missy Miller, medical outreach director at The Mesothelioma Center. She made the request with the Social Security disability office almost a year ago on behalf of a patient.
The Compassionate Allowances program is reserved for severe medical diseases and conditions that automatically meet Social Security standards for disability benefits. It cuts short the often drawn-out application proces...
Source: Asbestos and Mesothelioma News - August 18, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Phase III study shows Roche's Polivy plus R-CHP is the first regimen in 20 years to significantly improve outcomes in previously untreated aggressive form of lymphoma compared to standard of care
Basel, 9 August 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the pivotal phase III POLARIX trial investigating Polivy ® (polatuzumab vedotin) in combination with MabThera®/Rituxan® (rituximab) plus cyclophosphamide, doxorubicin and prednisone (R-CHP) versus MabThera/Rituxan plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP), met its primary endpoint by demonstrating significantly improved an d clinically meaningful progression-free survival in people with previously untreated diffuse large B-cell lymphoma (DLBCL). Safety outcomes were consistent with those seen in previous trials....
Source: Roche Investor Update - August 9, 2021 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Phase III study shows Roche's Polivy plus R-CHP is the first regimen in 20 years to significantly improve outcomes in previously untreated aggressive form of lymphoma compared to standard of care
Basel, 9 August 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the pivotal phase III POLARIX trial investigating Polivy ® (polatuzumab vedotin) in combination with MabThera®/Rituxan® (rituximab) plus cyclophosphamide, doxorubicin and prednisone (R-CHP) versus MabThera/Rituxan plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP), met its primary endpoint by demonstrating significantly improved an d clinically meaningful progression-free survival in people with previously untreated diffuse large B-cell lymphoma (DLBCL). Safety outcomes were consistent with those seen in previous trials....
Source: Roche Media News - August 9, 2021 Category: Pharmaceuticals Source Type: news
PET/MRI advances efforts for virtual biopsy in breast cancer
FDG-PET/MRI combined with ultrasound could reduce the need for invasive biops...Read more on AuntMinnie.comRelated Reading:
PET imaging shows how COVID vaccines confound cancer detection
PET tracers reveal long-term consequences of brain injuries
PET/MRI study looks at head injuries and Alzheimer's disease
When will PET/MRI live up to its promise?
FDG-PET/MRI offers option for pediatric Hodgkin lymphoma (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - May 27, 2021 Category: Radiology Source Type: news
Roche to present data from one of the most comprehensive oncology portfolios at the 2021 ASCO Annual Meeting showcasing advancements for people living with cancer
Basel, 11 May 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data from clinical trials of 19 approved and investigational medicines across 20 cancer types will be presented at the 2021 ASCO Annual Meeting, which will be held 4-8 June, 2021. A total of 132 abstracts that include a Roche medicine will be presented at this year ' s meeting. These data advance oncology by showing the importance of making patient-centric treatment decisions and providing tailored medical care based on specific cancer types.“We will be presenting data from across our diverse oncology portfolio that has the potential to help...
Source: Roche Media News - May 11, 2021 Category: Pharmaceuticals Source Type: news
Roche to present data from one of the most comprehensive oncology portfolios at the 2021 ASCO Annual Meeting showcasing advancements for people living with cancer
Basel, 11 May 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data from clinical trials of 19 approved and investigational medicines across 20 cancer types will be presented at the 2021 ASCO Annual Meeting, which will be held 4-8 June, 2021. A total of 132 abstracts that include a Roche medicine will be presented at this year ' s meeting. These data advance oncology by showing the importance of making patient-centric treatment decisions and providing tailored medical care based on specific cancer types.“We will be presenting data from across our diverse oncology portfolio that has the potential to help...
Source: Roche Investor Update - May 11, 2021 Category: Pharmaceuticals Source Type: news
Combo Provides'Broad Benefit' Across NHL Subtypes Combo Provides'Broad Benefit' Across NHL Subtypes
The combination of copanlisib + rituximab led to a reduction in the risk for disease progression/death when compared with rituximab + placebo in patients with relapsed, indolent non-Hodgkin lymphoma.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 13, 2021 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
AACR: Copanlisib + Rituximab Slows Relapsed Indolent Lymphoma
TUESDAY, April 13, 2021 -- Copanlisib plus rituximab (C+R) reduces disease progression or death in patients with relapsed indolent non-Hodgkin lymphoma (iNHL), according to a study presented during Week 1 of the annual meeting of the American... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 13, 2021 Category: Pharmaceuticals Source Type: news
Combination-copanlisib-rituximab-significantly-increases-progression-free-survival-patients-relapsed
Copanlisib is the first and only PI3K inhibitor to demonstrate broad and superior efficacy in combination with rituximab in patients with relapsed indolent non-Hodgkin’s Lymphoma (iNHL) compared to rituximab and placebo / Phase III trial CHRONOS-3 showed the combination of copanlisib and rituximab resulted in a 48% reduction in the risk of disease progression or death in patients with iNHL / The strong reduction in risk of progression or death was observed across all prespecified iNHL subtypes / The adverse event (AE) profile of the copanlisib and rituximab combination was manageable and generally consistent with pre...
Source: Bayer Company News - April 10, 2021 Category: Pharmaceuticals Source Type: news
Cancer symptoms: Painless swellings may be a sign of non-Hodgkin lymphoma
CANCER will affect one in two of us, meaning 50 percent of the British population will get the deadly disease in their lifetime. What are the early warning signs of non-Hodgkin lymphoma? (Source: Daily Express - Health)
Source: Daily Express - Health - March 24, 2021 Category: Consumer Health News Source Type: news
